TD, an endpoint which takes CBPD into consideration in the efficacy assessment, appears more reasonable and accurate to reflect the real efficacy of crizotinib among unselected ALK‐positive NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.